Quantum Leap Healthcare Collaborative
search

I-SPY Clinical Sites

Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
City of Hope
Cleveland Clinic
Columbia University
Emory
Georgetown University
Hoag Hospital
Loyola University
Masonic Cancer Center, University of Minnesota
Mayo Clinic
Moffitt Cancer Center
Ohio State University
Oregon Health & Science University
Rutgers Cancer Institute of New Jersey
Sanford Health
Sparrow
Swedish Cancer Institute
UAB
UC Davis
UCSD
UCSF
UPMC
USC
University of Chicago
University of Colorado, Denver
University of Pennsylvania
University of Rochester
University of Utah, Huntsman
Vanderbilt
Wake Forest
Yale